Since most patients are diagnosed at an advanced stage, ovarian cancer remains the most deadly gynecologic malignancy. There is no single biomarker with the required sensitivity and specificity.
Department of Obstetrics and Gynecology, Yale University School of Medicine, Harvard University Brigham and Women's Hospital (BWH), Dana Farber Cancer Institute, Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center, etc. A new set of biomarkers was developed jointly for the early detection of high-grade serous ovarian cancer. The results were published in the latest authoritative journal of Obstetrics and Gynecology: Gynecologic Oncology.
Clinical research design:
Candidate factors: 12: IL-1Ra, IL-6, Dkk-1, uPA, E-CAD, ErbB2, SLPI, HE4, CA125, LCN2, MSLN, and OPN
Study subjects: 172 patients (with gynecological benign lesions, or high-grade serous ovarian adenocarcinoma, etc.)
Technology Platform: Ella Simple Plex (ProteinSimple)
RESULTS: The panel consisting of CA125, HE4, E-CAD, and IL-6 has a clinical value for the specific diagnosis of serous ovarian cancer.
a) ovarian cancer patients versus no tumor control group: specificity 100% , positive predictive value 100% , sensitivity 86.4%
b) ovarian cancer patients versus gynecological benign disease control group: specificity 100% , positive predictive value 100% , sensitivity 87.2%
c) ovarian cancer patients versus no gynecological benign disease control group: specificity 100% , positive predictive value 100% , sensitivity 98.4%
d) Early serous ovarian cancer Versus tumor-free control group: specificity 95.7% , positive predictive value 88.9% , sensitivity 84.2%
In this article, the author specifically points out the reasons for choosing Ella simple plex for this study:
Our study is one such effort to identify a panel of multiple serum biomarkers which is not just sensitive and specific, but also time-efficient and cost-effective. Simple PlexTM is a new multi-analyte immunoassay platform, which has been proven to have significant advantages over traditional approaches in terms of low volume requirements (2.5 to 25 μL), sensitivity, and reproducibility [34,35]. Simple Plex ™ eliminates inconsistency in sample handling and produces results in a short amount of time, thus providing results with Minimal error and in timely fashion . Simplex PlexTM costs much less and would be more cost-efficient to analyze multiple biomarkers.
Original information:
A novel multiple biomarker panel for the early detection of high-grade
Serous ovarian carcinoma, C. Han et al. / Gynecologic Oncology xxx (2018) xxx–xxx, https://doi.org/10.1016/j.ygyno.2018.03.050.
Author unit:
1. Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA
2. Department of Biostatistics, University of Arkansas for Medical Science, Little Rock, AR 72205, USA
3. Department of Cancer Biology, Department of Oncologic Pathology, Blais Proteomic Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA
4. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
5. Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
6.Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
7. Division of Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA
8. Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
9.Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06510, USA
For more updates, please contact ProteinSimple. Follow ProteinSimple official WeChat
Foot Spa Massager,Bath Foot Massager Machine,Foot Spa Bath,Bath Foot Massager With Bubble
Huaian Mimir Electric Appliance Co., LTD , https://www.mmfootspa.com